So-Young International (SY) - Forward P/S Multiple

Symbol and logo of brand So-Young International Inc. (SY)

So-Young International (SY) is developing a Chinese aesthetic medicine marketplace driven by a powerful network effect. Growth is based on the digitalization of clinics and AI-driven personalization, although strict government regulatory oversight is constraining expansion. The change in the projected P/S ratio visualizes market revenue expectations, while the value of 0.70 corresponds to the current metric, capturing the business's investment cycle stage.

SY So-Young International Inc: Market Cap to Projected Revenue in the range 07/04/2022 - 11/15/2026

SY (soyoung.com): analytical breakdowns and indicator data

- stock price and consensus target price:
- market capitalization indicators:
Summary company analysis:SY (So-Young International)
Product sample of So-Young International

Forward P/S determines the market value of a business relative to projected revenue, allowing for an assessment of the justification for the control premium over assets. By analyzing the future P/S dynamics of So-Young International (SY), an investor can compare market expectations with the monetization of the partner clinic base, where a stable multiple confirms the efficiency of extracting profit from the platform's dominant position in the Chinese aesthetic medicine sector.

Competitor analysis for So-Young International

Price-to-Projected Revenue Ratio Veeva Corp VEEV|Price to Expected Revenue Ratio DOCS (Doximity, Inc.)|HQY: Forward Price-to-Revenue Multiple|Forward Price to Sales WAY (waystar.com)|CorVel Corp. (CRVL) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Privia Health (PRVA)|Price-to-Projected Revenue Ratio Huron Corp|Market Cap to Projected Revenue CERT (Certara Corp)|Price-to-Projected Revenue Ratio Omnicell (OMCL)|GoodRx Holdings, Inc. - Market Cap to Projected Revenue|Schrödinger - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio Phreesia Inc (PHR)|OMDA: Forward Price-to-Revenue Multiple|Forward Price to Sales EVH (Evolent Health, Inc.)|HSTM: Forward P/S Multiple|DH: Price to Expected Revenue Ratio|CCSI (Consensus) - Forward P/S Multiple|Price-to-Projected Revenue Ratio AGL|Forward P/S Multiple ABSI|NRC (National Research Corp) - Forward Price to Sales|Forward P/S Multiple SPOK (spok.com)|Forward Price to Sales OPRX|trubridge.com - Forward P/S Multiple|SLP (Simulations Plus) - Market Cap to Projected Revenue|SOPHiA GENETICS SA (SOPH) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Health Catalyst, Inc.|Forward Price-to-Revenue Multiple CCLD|researchsolutions.com (RSSS) - Market Cap to Expected Sales Ratio|Forward P/S Multiple DLHC|OneMedNet Corp - Market Cap to Projected Revenue|Forward P/S Multiple SCNX (Scienture Corp)|Price to Expected Revenue Ratio HCTI (Healthcare Triangle Corp)|iSpecimen Corp - Forward P/S Multiple|Forward Price to Sales BFRG (bullfrogai.com)|WORX: Forward P/S Multiple|Forward Price-to-Revenue Multiple MSP Recovery|Price-to-Projected Revenue Ratio icoreconnect.com|MEDS: Forward Price to Sales|Price-to-Projected Revenue Ratio Orgenesis Inc. (ORGS)|Market Cap to Expected Sales Ratio R1 RCM, Inc.|Forward P/S Multiple SHCR (sharecare.com)|Market Cap to Expected Sales Ratio Streamline Health Solutions, Inc. (STRM)|SYRA - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Apollo Medical Holdings Inc. AMEH|Model N (MODN) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue NXGN